Cargando…

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study

PURPOSE: The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio (LNR) in patients with breast cancer after neoadjuvant chemotherapy. MATERIALS AND METHODS: This retrospective analysis is based on the data of 814 patientswith stage II/III breast cancer treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Se Hyun, Jung, Kyung Hae, Kim, Tae-Yong, Im, Seock-Ah, Choi, In Sil, Chae, Yee Soo, Baek, Sun Kyung, Kang, Seok Yun, Park, Sarah, Park, In Hae, Lee, Keun Seok, Choi, Yoon Ji, Lee, Soohyeon, Sohn, Joo Hyuk, Park, Yeon-Hee, Im, Young-Hyuck, Ahn, Jin-Hee, Kim, Sung-Bae, Kim, Jee Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080811/ https://www.ncbi.nlm.nih.gov/pubmed/27034147 http://dx.doi.org/10.4143/crt.2015.475

Ejemplares similares

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
por: Moon, Yong Wha, et al.
Publicado: (2013)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lee, Soohyeon, et al.
Publicado: (2022)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
por: Kim, Nalee, et al.
Publicado: (2023)

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
por: Lee, Jiyun, et al.
Publicado: (2021)

Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
por: Lee, Soohyeon, et al.
Publicado: (2020)

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
por: Kim, Hee-Jun, et al.
Publicado: (2015)

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
por: Park, Yeon Hee, et al.
Publicado: (2017)

Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
por: Kim, Chang Gon, et al.
Publicado: (2016)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane
por: Koh, Hyeon Kang, et al.
Publicado: (2016)

Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis
por: Park, Jin Hyun, et al.
Publicado: (2017)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes
por: Kim, Sang-Won, et al.
Publicado: (2016)

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2015)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society
por: Ryu, Jai Min, et al.
Publicado: (2022)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
por: Jung, Hae Hyun, et al.
Publicado: (2016)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
por: Lee, Ki Hyeong, et al.
Publicado: (2015)

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
por: Lee, Yong-Pyo, et al.
Publicado: (2022)

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
por: Lee, Dae-Won, et al.
Publicado: (2023)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Hae Hyun, et al.
Publicado: (2023)

Body Mass Index with Tumor (18)F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer
por: Hyun, Seung Hyup, et al.
Publicado: (2016)

High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization
por: Ahn, Jin Seok, et al.
Publicado: (2005)

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
por: Lee, Kyung-Hun, et al.
Publicado: (2007)

Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication
por: Kim, Min Hwan, et al.
Publicado: (2015)

Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Park, Jin Hyun, et al.
Publicado: (2017)

Permanent Chemotherapy‐Induced Alopecia in Patients with Breast Cancer: A 3‐Year Prospective Cohort Study
por: Kang, Danbee, et al.
Publicado: (2018)

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
por: Park, Kyunghee, et al.
Publicado: (2015)

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7qbpbr2kgc7v6nnoroc3lsqbi2